Platek Anna E, Szymanska Anna
Department of Biophysics, Physiology and Pathophysiology, Medical Univeristy of Warsaw, Warsaw, Poland.
Department of Civilization Diseases, Collegium Medicum, Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland.
Clin Exp Hepatol. 2023 Sep;9(3):187-192. doi: 10.5114/ceh.2023.130744. Epub 2023 Aug 28.
In recent years, the diagnosis and understanding of nonalcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic liver disease (MASLD), and its relationship with cardiovascular diseases (CVD) are gaining better understanding. As MASLD shares common risk factors with CVD, including obesity, insulin resistance, hypertension, and dyslipidemia, research increasingly identifies it as a potential independent risk factor for CVD. The exact mechanisms linking MASLD to CVD remain complex and multifaceted, involving metabolic, inflammatory, and vascular pathways. Current cardiology guidelines recognize the significant association between MASLD and CVD, advocating its integration into cardiovascular risk assessment and management. Despite the progress, gaps persist in understanding underlying molecular and cellular mechanisms and the representation of diverse populations in epidemiological studies. The review illuminates the clinical implications of the MASLD-CVD link and identifies directions for future research.
近年来，非酒精性脂肪性肝病（NAFLD），最近重新定义为代谢功能障碍相关脂肪性肝病（MASLD），其诊断、认识以及与心血管疾病（CVD）的关系正得到更好的理解。由于MASLD与CVD有共同的危险因素，包括肥胖、胰岛素抵抗、高血压和血脂异常，研究越来越多地将其确定为CVD的潜在独立危险因素。将MASLD与CVD联系起来的确切机制仍然复杂且多方面，涉及代谢、炎症和血管途径。当前的心脏病学指南认识到MASLD与CVD之间的显著关联，主张将其纳入心血管风险评估和管理。尽管取得了进展，但在理解潜在的分子和细胞机制以及流行病学研究中不同人群的代表性方面仍存在差距。这篇综述阐明了MASLD与CVD关联的临床意义，并确定了未来研究的方向。
